Oncotarget

Research Papers:

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis

Sandeep S. Negi _ and Patrick Brown

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:18094-18104. https://doi.org/10.18632/oncotarget.4093

Metrics: PDF 1417 views  |   HTML 1737 views  |   ?  


Abstract

Sandeep S. Negi1, Patrick Brown1

1Department of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence to:

Patrick Brown, e-mail: pbrown2@jhmi.edu

Keywords: CX-5461, rRNA synthesis, ATM/ATR pathway, G2/M arrest, acute lymphoblastic leukemia

Received: April 08, 2015     Accepted: May 23, 2015     Published: June 05, 2015

ABSTRACT

Ribosome biogenesis is a fundamental cellular process and is elevated in cancer cells. As one of the most energy consuming cellular processes, it is highly regulated by signaling pathways in response to changing cellular conditions. Many of the regulators of this process are aberrantly activated in various cancers. Recently two novel rRNA synthesis inhibitors, CX-5461 and BMH-21, have been shown to selectively kill cancer cells while sparing normal cells. Here, we tested the effectiveness of pre-rRNA synthesis inhibitor CX-5461 on acute lymphoblastic leukemia cells with different cytogenetic abnormalities. Acute lymphoblastic leukemia cells are more sensitive to rRNA synthesis inhibition compared to normal bone marrow cells. CX-5461 treated cells undergo caspase-dependent apoptosis independent of their p53 status. More-over, CX5461, activates checkpoint kinases and arrests cells in G2 phase of cell cycle. Finally, overcoming this G2 arrest by inhibiting ATR kinase leads to robust cell killing. These results show that CX-5461 can be even more potent in combination with ATR inhibitors.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4093